Amgen Inc

This proposal asks shareholders to approve, on a non-binding advisory basis, the compensation paid to Amgen’s Named Executive Officers as disclosed in the proxy. Management is seeking approval to confirm its approach to executive pay, which emphasizes long-term, performance-based equity awards (80% of grants are performance-based) and a mix of annual cash incentives tied to rigorous financial and operational goals. The company highlights strong 2025 financial performance, pipeline progress, and operational execution as justification for pay outcomes, and stresses governance safeguards—stock ownership guidelines, clawbacks, recoupment policies, independent compensation consultant, and majority voting—to mitigate risk and align pay with stockholder interests. A FOR vote supports management’s retained discretion to implement its compensation program; a negative vote would signal investor discontent and likely prompt increased engagement and possible program changes. The Board recommends FOR, citing alignment of pay with performance and stockholder value creation. Institutional investors and proxy advisory firms typically evaluate say-on-pay on program design, disclosure, and realized pay relative to performance; Amgen’s large performance weighting and clear KPI linkages are central to management’s defense. The advisory nature of the vote means the Board will consider but is not bound by the result; historically Amgen received strong say-on-pay support and uses outreach to refine compensation governance. In evaluating the proposal, investors should weigh the firm’s 2025 operational and financial achievements, long-term equity mix, recoupment mechanisms, and responsiveness to stockholder feedback against concerns about absolute award sizes and retention practices. Overall, the proposal is primarily a governance confirmation vote rather than a specific policy change, and its passage would affirm the Board’s current compensation framework.

The shareholder proposal, submitted by John Chevedden, asks Amgen to amend its governing documents to require the Board Chair be an independent director and to separate the roles of Chair and CEO, arguing that an independent chairman would provide impartial oversight, reduce conflicts of interest, increase transparency, and strengthen accountability—particularly in light of recent business challenges such as patent expirations, pricing pressure, impairment charges, product concerns, and elevated leverage. The proponent’s case emphasizes that a detached independent chair would better focus on shareholder interests and checks-and-balances. Management and the Board oppose the proposal, arguing that Amgen’s existing governance (an annually elected lead independent director with robust duties, independent majority of directors, independent committee leadership, annual leadership structure reviews, strong stockholder rights and engagement) provides effective oversight while retaining flexibility to choose the most effective leadership structure. The Board contends mandatory separation would remove discretion to tailor leadership to company needs and could weaken governance; it cites Amgen’s strong 2025 operational and financial performance, significant R&D investments, and ongoing stockholder engagement as evidence the current structure is effective. For a sophisticated evaluation, key considerations include: the practical difference between a lead independent director with defined authorities versus an independent chair, the Board’s track record of exercising oversight during recent headwinds, the company’s responsiveness to stockholder feedback, and whether an independent chair would materially alter incentives or oversight effectiveness given Amgen’s committee structure and policies. Investors should assess empirical governance outcomes (frequency and content of executive sessions, lead director activities, committee independence and actions, CEO performance evaluation process) and consider whether formal separation would likely produce better monitoring or is largely symbolic at Amgen given its existing safeguards. The decision also interacts with succession planning: if separation would be phased or triggered by a CEO contract renewal or transition, the practical impact depends on transition timing and the Board’s criteria for selecting an independent chair. Ultimately, the vote represents a trade-off between prescriptive governance reform favored by some investors and the Board’s preference for flexible, context-dependent leadership arrangements supported by a strong lead independent director role.